Home » Topics » BioWorld Science

BioWorld Science
RSS

Bioway describes novel PI3Kdelta/PI3Kgamma inhibitors

Feb. 7, 2018

Lifesci Pharmaceuticals discloses new plasma kallikrein inhibitors

Feb. 7, 2018

Actinium to study Actimab-A with CLAG-M in relapsed or refractory AML

Feb. 7, 2018

Bavarian Nordic reports results from phase III pivotal study of smallpox vaccine

Feb. 7, 2018

Novel PAR-4 antagonists discovered at Bristol-Myers Squibb

Feb. 7, 2018

First patient treated in phase II study of Imprime PGG in combination with Keytruda

Feb. 7, 2018

Zogenix's ZX-008 granted FDA breakthrough therapy designation

Feb. 7, 2018

Servier and ImmunoQure to collaborate on the development of an interferon-alpha human autoantibody

Feb. 7, 2018

Topline data presented from phase II study of NGM-282 in primary sclerosing cholangitis

Feb. 7, 2018

Positive topline phase III results from ACHIEVE I study of ubrogepant

Feb. 7, 2018

Popular Stories

NIH changes set industry up for workforce, ideas drought
BioWorld
On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...
Today's news in brief
BioWorld
BioWorld briefs for March 14, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for March 13, 2025
At CROI, HIV cure trials raise hopes for broader applicability
BioWorld
At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full...
Hummingbird migrates ADCs, tech to newco Callio’s $187M debut
BioWorld
Antibody-drug conjugate (ADC)-focused Callio Therapeutics debuted on March 3 with the closing of a $187 million series A financing round based on cancer drug...